CHICAGO — In this video, Adam Cohen, MD, discussed findings from the DREAMM-7 and DREAMM-8 trials presented at ASCO Annual Meeting.
The trials combined belantamab mafodotin (Blenrep, GSK) with standard-of-care treatments in patients with relapsed/refractory multiple myeloma. Both trials met their primary endpoints.
“I think we’re looking at longer follow-ups, looking at survival,” Cohen, associate professor of medicine in hematology-oncology at Hospital of the University of Pennsylvania, said. “But I suspect that this may lead to the reemergence of these belantamab
